A Phase 1, Open-label, Randomized, 2-Part, 2-Way Crossover Study in Healthy Adult Participants to Assess the Relative Bioavailability of Tablet Formulations of Lazertinib

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502814-99-00

Enrollment

Registered

2023-04-05

Start date

2023-05-30

Completion date

2023-09-01

Last updated

2023-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer (NSCLC)

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Belgium

None listed

Source: EU CTIS · Data processed: Feb 4, 2026